Investor village ISIS board post #46042
OS benefit could be as low at 2.6 months for Synergy trial based on Phase 2b trial OS survival data of 16.9 months from Placebo group.
16.9 months + 15% is a pretty low hurdle to have to clear. It's a little more challenging, however, if the control group's OS was 20 months or more. Not saying it did or didn't happen - just repeating what others here have noted. .